These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19568281)

  • 1. Everolimus.
    Atkins MB; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Jul; 8(7):535-6. PubMed ID: 19568281
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
    Bukowski RM
    Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
    [No Abstract]   [Full Text] [Related]  

  • 4. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
    Mizuno R; Miyajima A; Oya M
    Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
    [No Abstract]   [Full Text] [Related]  

  • 5. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.
    Loron MC; Grange S; Guerrot D; Di Fiore F; Freguin C; Hanoy M; Le Roy F; Poussard G; Etienne I; Legallicier B; Pfister C; Godin M; Bertrand D
    J Clin Oncol; 2015 Mar; 33(8):e45-7. PubMed ID: 24638002
    [No Abstract]   [Full Text] [Related]  

  • 6. [Everolimus (RAD001/Afinitor) in the treatment of metastatic cell carcinoma].
    Gennigens C; Sautois B; Jerusalem G
    Rev Med Liege; 2010 Apr; 65(4):212-6. PubMed ID: 20499824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus.
    Houghton PJ
    Clin Cancer Res; 2010 Mar; 16(5):1368-72. PubMed ID: 20179227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
    Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
    Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
    [No Abstract]   [Full Text] [Related]  

  • 10. Everolimus in renal cell carcinoma.
    Wang Y
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
    Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
    Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
    Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
    Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR pathway inhibition in renal cell carcinoma.
    Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
    Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma.
    Rodriguez-Pascual J; Cheng E; Maroto P; Duran I
    Anticancer Drugs; 2010 Jun; 21(5):478-86. PubMed ID: 20401967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
    Procopio G; Verzoni E; De Braud F
    Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of everolimus in renal cell cancer.
    Amato R; Stepankiw M
    Expert Opin Pharmacother; 2013 Jun; 14(9):1229-40. PubMed ID: 23578333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma.
    Harshman LC; Barbeau S; McMillian A; Srinivas S
    Clin Genitourin Cancer; 2013 Jun; 11(2):100-6. PubMed ID: 23352238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.